Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of ...

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

A study by the Neuropsychopharmacology and IBeA groups of the University of the Basque Country (UPV/EHU) paves the way to ...

The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...